Seeking Alpha · 14 Sept 2026neutral
enGene Therapeutics Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item records the company's participation in the conference.
Why it matters — The conference appearance gives investors and ENGN watchers access to the company's stated updates and commentary on its business outlook.
Seeking Alpha · 10 Sept 2026neutral
The article discusses enGene Therapeutics' efforts to reduce cash burn, including a 50% workforce reduction that extends its cash runway into 2029, while noting FDA approval risk for its lead asset, detalimogene voraplasmid, due to weak 12-month durability. Management is pursuing a surfactant cohort to address efficacy ahead of pivotal BLA milestones.
Why it matters — ENGN watchers would care because cost-cutting measures could support the company through pivotal regulatory milestones for its lead candidate despite approval risk.
Business Wire · 8 Sept 2026neutral
enGene Therapeutics reported its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. The company noted its focus for the second half of 2026 includes maturing regulatory endpoint data from the LEGEND pivotal cohort and planned engagement with the FDA regarding a BLA filing for detalimogene.
Why it matters — The update signals progress toward a potential BLA filing for detalimogene and highlights upcoming regulatory milestones that ENGN watchers would track closely.
Business Wire · 1 Sept 2026neutral
enGene Therapeutics announced that its management will participate in upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, both in fireside chat format. The announcement was made via Business Wire from Boston and Montreal.
Why it matters — For ENGN watchers, this signals that company management will have scheduled public engagements at major financial conferences, offering opportunities to hear directly from leadership about the company's clinical-stage non-viral genetic medicines programs.
MarketBeat · 13 Aug 2026positive
enGene outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy, with an eye toward 2027 approval for detalimogene.
Why it matters — An ENGN watcher would care because the company is presenting a market opportunity for detalimogene that could underpin its development timeline toward a 2027 approval.
